OptimizeRx Corporation has introduced CopayCue™, a new solution that integrates real-time prescribing intent data to deliver brand savings offers, such as copay cards, directly within the electronic prescribing workflow. This innovation aims to reduce cost barriers for patients and improve prescription fill rates by providing physicians with transparent savings information at the moment they decide to prescribe. CopayCue leverages data from over 400 electronic health record and e-prescribing platforms, engaging 900,000 healthcare professionals to increase prescription conversions by up to 11.5%. This tool supports life sciences companies in enhancing patient access to therapies and improving marketing effectiveness by linking financial assistance directly to prescriber intent.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
